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Abstract
Purpose of Review Dietary interventions (DI) aimed at improving overweight and metabolic abnormalities in metabolic
dysfunction-associated fatty liver disease (MAFLD) and at reducing malnutrition and sarcopenia in cirrhosis should become
part of routine care in hepatology. This review focuses on recent advances in this field.
Recent Findings In patients with MAFLD, a gradual reduction, respectively, of 7–10% of body weight if overweight or of 3–5%
if lean, obtained by moderately reducing caloric intake, is effective to improve liver disease. Intermittent energy restriction might
be an alternative to continuous energy restriction with higher adherence. Qualitative dietary adjustments should include increased
intake of unprocessed foods including fruits and vegetables, whole grains, fiber, and unsaturated fatty acids (FAs), for example,
through a Mediterranean diet. Refined carbohydrates (CHOs), saturated FA (SFAs), red meat, and processed meat should be
limited. DI studies in HIV-infected subjects with MAFLD are very limited, and this is a field for future research. In patients with
cirrhosis, DI should aim at correcting malnutrition and improving skeletal muscle mass. Daily diet contents should aim at
achieving 30–35 kcal/kg of body weight, including 1.2–1.5 g/kg proteins, and oral or enteral supplementation might be used
in patients unable to achieve these targets. In some studies, branched-chain amino acids (BCAAs) proved to be effective in
improving muscle mass and were associated with a lower risk of hepatic encephalopathy. Obesity requires adjustment of the
above-mentioned targets, and its management is challenging. Studies looking at the efficacy of DI recommended by the existing
guidelines on clinical endpoints are a field for future research.
Summary Dietary interventions are able to improve MAFLD and show potential to reduce complications in liver disease. Despite
its key importance, there are many barriers limiting the implementation of DI in patients with chronic liver disease. Patients’
empowerment is crucial and should be the focus of specific educational programs. In addition, liver clinics would benefit from
multidisciplinary teams involving experts in nutrition, physical exercise, primary care physicians, and psychologists when needed.
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Introduction
The liver is a key organ for the metabolism of proteins, fats, and
carbohydrates (CHOs). Not surprisingly, liver health is strictly
related tometabolic health. Fatty liver disease has become high-
ly prevalent in the general population, mostly driven by exces-
sive food/calorie intake along with sedentary behavior as well
as genetic and environmental factors (e.g., exposure to
chemicals leading to alterations of the gut microbiome [1]),
leading to obesity and metabolic dysfunction. Among the ge-
netic factors modulating the risk ofMAFLD and its progression
to cirrhosis and hepatocellular carcinoma, confirmed associa-
tions include single-nucleotide polymorphisms in patatin-like
phospholipase domain-containing 3 (PNPLA3), transmem-
brane 6 superfamily member 2 (TM6SF2), glucokinase
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regulatory protein gene (GCKR), and HSD17B13, encoding
for a retinol dehydrogenase [2•].
MAFLD is also more frequent in people living with HIV
(PLWH) [3–5], likely due to the inflammation and bacterial
translocation related to HIV infection per se, as well as life-
long antiretroviral therapy (ART) [6, 7]. Although older drugs
most likely to cause lipodystrophy are not used anymore,
newer antiretroviral drugs, such as dolutegravir and tenofovir
alafenamide (TAF), remain associated with metabolic side
effects and weight gain [8–10] as classic metabolic risk factors
for MAFLD [11, 12].
On the other hand, protein–calorie malnutrition is frequent
in patients with liver disease in the cirrhotic stage due to sev-
eral mechanisms. Cirrhosis implies impaired hepatic and skel-
etal muscle glycogen synthesis and storage, increased protein
catabolism, and increased lipolysis. In addition, portal hyper-
tension leads to malabsorption through impaired gut motility,
dysbiosis and mucosal changes, and decompensated disease.
The latter often features systemic inflammation and ascites,
conditions requiring increased caloric intake which cannot be
easily matched due to loss of appetite, resulting in severe
malnutrition and sarcopenia. Genetic and environmental fac-
tors in this specific setting have not been investigated so far.
This review will provide an update on the existing dietary
interventions to improve the nutritional status of patients with
chronic liver disease, focusing on the two most prevalent con-
ditions, namely, metabolic dysfunction-associated liver dis-
ease (MAFLD)/metabolic dysfunction-associated
steatohepatitis (MASH) (previously termed more generically
non-alcoholic fatty liver disease, NAFLD, and non-alcoholic
steatohepatitis, NASH) and cirrhosis.
Nutritional Interventions in MAFLD/MASH
While no pharmacological therapy is approved for the treat-
ment of MAFLD, several international guidelines, including
HIV guidelines, advocate the use of lifestyle interventions,
often including dietary interventions (DI) [13–15], due to the
direct link between MAFLD and comorbid metabolic disor-
ders such as obesity and diabetes mellitus type 2, in which
such interventions have been proven effective. It should be
noted that genetic and environmental factors, which are
known to modulate comorbid metabolic conditions, may also
mediate the individual response to DI and lifestyle interven-
tions in general. Future studies are needed to further investi-
gate these possible effects.
Interventional studies on nutrition in MAFLD cover a
broad spectrum of dietary measures (Table 1). The main cat-
egories include energy restriction through changes in dietary
composition and certain patterns of food intake such as
fasting, as well as changes in the composition of macronutri-
ents and micronutrients, including dietary supplements and
specific foods. Many studies use a combination of these mea-
sures, making direct comparison of the results challenging.
Fig. 1a summarizes the suggested DI for MAFLD and asso-
ciated comorbid conditions and areas of uncertainty.
Energy/Calorie Restriction
Several trials have been able to demonstrate the beneficial
effects of weight loss on liver enzymes as well as histological
outcomes such as steatosis and inflammation, although the
evidence regarding fibrosis is less conclusive [34, 35•].
Besides surgical interventions or pharmacotherapy, weight
loss can be achieved through dietary measures limiting energy
intake, sometimes in combination with increased physical ex-
ercise (PE), which may also include increased physical activ-
ities of daily living or medications [36, 37]. Generally, DI
using caloric restriction can be classified into continuous and
intermittent energy restriction, although such a strict distinc-
tion is not always possible.
A major concern with diets that include energy restriction or
other comprehensive dietary adjustments is the lack of sustain-
ability of weight loss. A brief report of the observational and
longitudinal TARGET-NASH cohort study recently demon-
strated that while around one third of over 2000 overweight
or obese individuals withMAFLD achieved a weight reduction
of ≥ 5% in standard clinical care, only 25% of these patients
were able to sustain this over a median follow-up of 39 months
[38]. Factors that negatively influence the sustainability of DI
and other lifestyle interventions include psychological, socio-
economic, physiologic, and genetic factors. A thorough discus-
sion of these factors is beyond the scope of this review, but
these have been excellently reviewed elsewhere [39].
Continuous Energy Restriction: Hypocaloric Diet
A hypocaloric diet is a form of continuous energy restriction,
usually involving a daily calorie deficit of 500–1000 kcal. In
the literature, hypocaloric diets are explored with or without
changes in macronutrient composition. In a randomized con-
trolled trial (RCT), an intervention that combined hypocaloric
diet and PE in obese patients with type 2 diabetes mellitus
showed a reduction of steatosis by nearly 80% in patients
who lost ≥ 10% of body weight compared to 14% in those
with less body weight loss [40]. In a 48-week lifestyle inter-
vention that included moderate calorie restriction with re-
duced fat intake as well as coaching on behavior and PE,
significant histological improvements in steatosis, parenchy-
mal inflammation, ballooning injury, and overall NAFLD ac-
tivity score, but not in the fibrosis stage, were observed in
patients who achieved the weight loss goal of ≥ 7% of body
weight compared to controls [41]. In a more recent trial from



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































hypocaloric low-fat diet and lost ≥ 10% of body weight had a
reduction of at least 1 point in the histological fibrosis score
[42]. Two studies suggested that lean patients may also expe-
rience MAFLD remission after the loss of 3–5% of body
weight through a hypocaloric diet [29•, 43].
Intermittent Energy Restriction: Intermittent Fasting
and Time-Restricted Feeding
Previous research has shown a significant increase in hepatic
steatosis when a hypercaloric diet was consumed with high
meal frequency compared to consumption of the same diet
through larger meals [44]. Intermittent energy restriction has
been proposed as an alternative to continuous energy restric-
tion. Most interventions can be classified into either intermit-
tent fasting, which implies a > 60% energy restriction on > 2
days per week, or time-restricted feeding, where the daily food
intake is limited to 8–10 h [45]. In a Malaysian study, 8 weeks
of intermittent fasting with alternate-day calorie restriction
resulted in the reduction of body weight and liver enzymes
as well as liver steatosis and stiffness compared to a habitual
diet [46]. A larger Chinese RCT randomized 271 MAFLD
patients to undergo intermittent fasting, time-restricted feed-
ing, or no intervention [20]. Both intermittent fasting and
Fig. 1 a Suggested dietary interventions for MAFLD and associated
comorbid conditions and areas of uncertainties. b Reported effects of
nutritional interventions on clinical endpoints in cirrhosis and areas of
uncertainties. Abbreviations used: MAFLD, metabolic associated fatty
liver disease; MD, Mediterranean diet; MUFAs, monounsaturated fatty
acids; PUFAs, polyunsaturated fatty acids; SFAs, saturated fatty acids;
BCAAs, branched-chain amino acids; LES, late evening snack; HCC,
hepatocellular carcinoma; ONS, oral nutritional supplementation; PNS,
parenteral nutritional supplementation
Curr Hepatology Rep
time-restricted feeding induced significant weight loss of
5.4% and 4.3%, respectively, while LDL, fasting insulin,
and liver stiffness did not differ significantly between groups.
Finally, satisfactory dietary adherence was reported in both
trials, which may indicate a possible advantage with regard
to sustainability compared to a hypocaloric diet.
Macronutrient Composition
Several trials have assessed the possible effects of macronu-
trient composition on MAFLD, but the overlap of different
interventions and effects limits the interpretation of results.
Fat Content
Several observational studies have demonstrated an associa-
tion between MAFLD and higher intake of SFAs as well as
decreased intake of polyunsaturated fatty acids (PUFAs), in-
dependently of total energy intake, suggesting that favoring
PUFAs over SFAs in the diet may improve MAFLD [47]. In
an RCT from Finland among 38 obese individuals,
intrahepatic triglycerides rose by 55% in those overfed with
SFAs, while the increase was 15% and 33% in the unsaturated
FA and CHO groups, respectively [48]. In a Swedish double-
blind RCT, despite similar weight gain in both groups, over-
weight subjects showed a 53% relative increase in intrahepatic
fat after overeating SFAs from palm oil compared to a 2%
decrease with omega-6 PUFAs from sunflower oil [22]. This
effect was more pronounced than what had been seen for
healthy lean subjects in a previous study [49]. An isocaloric
diet containing monounsaturated fatty acids (MUFAs) signif-
icantly decreased liver fat fraction by MRI and improved in-
sulin sensitivity compared to a regular or fiber-rich diet over
12 weeks [50].
This has inspired several trials on supplementing unsatu-
rated FAs, such as omega-3 FAs, which showed generally
beneficial effects on metabolic factors and liver fat content,
although substantial heterogeneity persists among trials [51,
52]. In a recent Australian study in 50 overweight males, sup-
plements containing omega-3 PUFAs from fish oil failed to
show a benefit on liver fat content over 12 weeks [53]. With a
high dose of 4 g/day for 8 weeks, a decrease of intrahepatic
triglycerides by 19% was noted with a supplement containing
omega-3 FA (eicosapentaenoic acid and docosahexaenoic ac-
id) [54]. One year supplementation with 3 g/day of fish oil,
however, did not improve histological activity in MASH pa-
tients [55]. Results from an Italian RCT suggest that an isoca-
loric diet, encompassing increased intake of MUFAs (from
extra virgin olive oil), omega-3 (from salmon), and omega-6
PUFAs (from almonds) as well as fiber and vitamins D, E, and
C,might bemore efficient in reducing liver fat than an isolated
MUFA diet [19]. This concept of synergistic combination of
nutrients is the basis of recommended diets such as the
Mediterranean diet (MD).
Carbohydrate Content
CHOs, especially the low CHO diet (LCD; < 50% of the total
energy intake from CHOs), have been investigated in the con-
text of MAFLD. A meta-analysis of LCD showed no reduc-
tion of liver enzymes, but a mean reduction of intrahepatic
lipid content by 11.5% in 4 studies, although significant het-
erogeneity was encountered [56]. Furthermore, the effect may
have been confounded by weight loss across intervention
groups. In 28 diabetic patients undergoing an isocaloric
high-protein LCD, a hepatic fat content reduction by 2.4%
compared to 0.2% under conventional diabetes diet was found
without significant weight loss [57]. Mardinoglu et al. (2018)
performed a multi-omics approach to characterize the meta-
bolic effects of CHO restriction on MAFLD and found an
increase in hepatic FA oxidation as well as reduced de novo
lipogenesis and hepatic steatosis after 2 weeks of isocaloric
high-protein LCD [58].
A subgroup of LCD studies has evaluated the effect of a
ketogenic diet, which induces a state of ketosis by significant
restriction of CHO intake, on MAFLD. A short-term
hypocaloric, ketogenic intervention in 10 overweight individ-
uals over 6 days increased nonesterified FAs, the main sub-
strate for intrahepatic triglycerides, but reduced intrahepatic
steatosis by 31%, while increasing insulin sensitivity and me-
tabolizing FAs towards ketogenesis [59]. In 262 diabetic pa-
tients who followed for 1 year an intervention based on LCD
to induce self-monitored ketosis, noninvasively suspected
steatosis and fibrosis resolved in 23% and 17% of patients,
respectively, while no changes occurred in the control group
[60]. However, evidence on the effects of a ketogenic diet in
humans is scarce, and no uniform definition of this diet exists.
More studies are needed to prove the safety of this approach in
the specific context of patients with liver disease — particu-
larly in those with advanced liver fibrosis.
As for the impact of free sugars, a meta-analysis failed to
prove a negative effect of fructose, which is often contained in
sweetened beverages and juices, on intrahepatic fat content in
an isocaloric diet [61]. Recently, an 8-week open-label RCT
of adolescent boys with histologically proven MAFLD, how-
ever, showed a mean difference of −6.2% in hepatic steatosis
after limiting the intake of free sugars to < 3% of the daily
caloric intake [62••].
Fiber Content
A diet rich in fiber is associated with a 15–30% reduction in
all-cause and cardiovascular mortality as well as a lower risk
for diabetes type 2 [63]. Several observational studies have
suggested a lower intake of fiber in MAFLD patients
Curr Hepatology Rep
compared to controls, although the exact impact is difficult to
assess as fiber intake is often part of broader dietary patterns
[64, 65]. Among 70 obese individuals who underwent 6
months of two hypocaloric dietary regimens with identical
energy deficit (RESMENA and AHA diets), the groups did
not differ with regard to the improvement of noninvasive
markers of liver health, and no association with macronutrient
composition was observed [66]. Higher insoluble fiber (≥ 7.5
g/day) and fiber from fruit consumption, however, were asso-
ciated with improvements of noninvasive scores and liver en-
zymes, respectively, indicating additional beneficial effects of
fiber consumption with energy restriction.
Protein Content
Several studies have examined the impact of high-protein di-
ets, often in combination with a hypocaloric regimen and
LCD, on hepatic health. In an Iranian study of 92 patients
who underwent a hypocaloric high-protein diet (25% of ener-
gy intake) with or without the addition of antioxidant β-
cryptoxanthin, the high-protein groups showed a greater re-
duction in liver enzymes, but weight loss may have mediated
this effect [16]. Among 19 bariatric patients, a hypocaloric
high-protein diet (30% of energy intake) over 3 weeks prior
to surgery led to a decrease of steatosis by 42.6% compared to
no effect under identical energy but lower protein intake [67].
Besides the amount of dietary protein, the source of pro-
teins remains an issue for debate. Red and processed meats
might contribute to MAFLD and other metabolic conditions,
due to the high content of SFAs, nitrites and nitrates, heme
iron, and branched-chain amino acids (BCAAs) which excess
may be deleterious [68, 69]. It has therefore been hypothe-
sized that a vegetarian diet may aid in reducing MAFLD and
other dysmetabolic conditions [70]. In a German study, 37
diabetic MAFLD patients were placed on a 6-week isocaloric
diet with high-protein intake either from animal or plant-based
sources [71]. While both diets reduced intrahepatic fat by 36–
48%, no negative metabolic effects of the omnivorous diet
were detected.
Specific Diets
The methods described earlier are often combined into
broader and comprehensive dietary patterns such as the MD.
The concept of the MD arose from the so-called Seven
Countries Study, where it was first noted that a certain dietary
pattern was linked to a decrease in cardiovascular disease and
mortality [72, 73]. While the MD generally contains plant-
based foods and legumes instead of red meat and saturated
FAs, direct comparison of trials is often hampered by the lack
of a uniform definition [74]. Two large studies comparing the
MDwith a low-fat, high CHO diet showed an improvement in
hepatic steatosis and insulin sensitivity [25, 75]. A greater
decrease in intrahepatic fat was seen under MD. Reduction
in ectopic fat deposits (including hepatic fat) was associated
with improved cardiometabolic risk independent of overall
weight loss [24]. Currently, the MD is the only specific diet
recommended by the European Association for the Study of
the Liver (EASL) guidelines [76].
It is unclear whether the recommendations used in the gen-
eral population can be applied also to PLWH, but given its
potential to lower the risk of lipodystrophy, MD may be fa-
vorable in PLWH.
Micronutrients, Supplements, and Specific Foods
A large body of research has focused on certain dietary com-
pounds in the treatment of MAFLD, sometimes in the form of
dietary supplements, a detailed summary of which is beyond
the scope of this review. Hepatoprotective effects have been
shown for an array of different foods, including antioxidants
such as vitamin E, as well as vitamin D probiotics and
synbiotics [77, 78]. Among more readily consumed specific
foods, the protective effect of coffee on MAFLD has recently
been confirmed by a meta-analysis of observational studies
that showed a pooled risk ratio of 0.68 for fibrosis in
MAFLD patients who consumed coffee regularly [79].
Nutritional Interventions in Patients
with Cirrhosis
Malnutrition is a common complication of cirrhosis. The nu-
tritional evaluation in cirrhosis is however challenging for a
variety of reasons: BMI (as well as DEXA) are affected by
fluid retention; common biomarkers such as albumin and
prealbumin are altered in the presence of impaired hepatic
synthetic function [80••, 81••]. The lack of a gold standard
to measure nutritional status in cirrhosis makes the study of
nutritional interventions in this population particularly
difficult.
Energy/Calorie Supplementation
Food intake is overall decreased in patients with cirrhosis,
while the metabolic demand is increased. Hence, the main
priority in nutritional interventions has been to provide an
adequate amount of calories to correct this imbalance.
Estimations based on indirect calorimetry and prior studies
have led to the current recommendations by the European
Society for Clinical Nutrition and Metabolism (ESPEN) and
the EASL, i.e., a daily caloric intake of 30–35 kcal/kg of dry
weight [80••, 81••]. In obese patients (BMI > 30 kg/m2) with
cirrhosis, a hypocaloric diet (−500–800 kcal/day) is recom-




The overall decreased food intake observed in cirrhosis is almost
invariably associated with an inadequate protein intake. The
current guidelines recommend a daily intake of 1.2–1.5 g/kg
of dry weight in nonobese individuals and >1.5 g/kg of ideal
body weight in obese individuals with cirrhosis [81••]. The pre-
vious fear of inducing hepatic encephalopathy (HE) with high-
protein diets (through hyperammonemia from protein deamina-
tion) is no longer a subject of debate, and protein restriction
should not be prescribed, as it may worsen sarcopenia, which
may in itself increase the risk of HE. Vegetable sources of pro-
tein could have additional benefits on HE given their lower
content in aromatic amino acids and their higher fiber content
compared to animal protein [81••]. A recent epidemiological
cohort study comparing Turkish and American patients with
cirrhosis suggested that coffee/tea, vegetable, and cereal con-
sumption were associated with a higher intestinal microbial di-
versity and a lower 90-day hospitalization rate [82].
BCAA Supplementation
BCAAs (leucine, isoleucine, and valine) are essential amino
acids involved in the metabolism of proteins, glucose, and fat
[83]. Their plasma levels are often low in patients with cirrho-
sis, especially in the presence of sarcopenia, hyperammonemia,
and HE. Two, earlier, well-designed studies (either using
isocaloric/isoproteic supplements as control interventions or
documenting similar calorie and protein intake in the BCAA
and control groups) have demonstrated that BCAA supplemen-
tation could prevent the progression of liver failure and liver-
related events in patients with cirrhosis [84, 85]. Since then,
numerous studies (coming predominantly from Japan; the most
recent are summarized in Table 2) have demonstrated a bene-
ficial effect on muscle strength, ascites, edema, and HE (Fig.
1b) [95•, 96]. Additionally, two recent meta-analyses conclud-
ed that BCAAs [97] or BCAA-based late evening snacks (LES)
[98] could help maintaining liver function after interventions
for hepatocellular carcinoma (HCC), preventing ascites, edema,
and HE. The beneficial effects of BCAAs may however be
overestimated in some studies since part of it could be attributed
to an overall increased calorie and protein intake in the BCAA
group compared to the control group. Additionally, it is unclear
if the severity of the liver disease has an impact on the response
to BCAA supplementation [89, 99].
Both the ESPEN and the EASL recommend in their latest
guidelines long-term oral BCAA supplementation when ade-
quate intake is not achieved by oral diet (which is almost invari-
ably the case in our personal experience) [80••, 81••]. However,
the optimal duration, dose, and amino acid ratio of BCAA sup-
plementation remain unclear. For instance, the dose used in
studies ranges between 5.5–30 g/day and 0.104–0.29 g/kg/day
(Table 2) [95•]. A recent retrospective Korean study compared
multiple doses and concluded that only the highest (12.45 g/day,
close to the ESPEN recommendation of 0.25 g/kg/day [80••])
was effective [100], while other studies have observed benefits
with doses as low as 6 g/day [86, 88]. Regarding the composi-
tion of BCAA supplements, the amino acid ratio varies slightly
in studies but approximates 2:1:1 of leucine, isoleucine, and
valine, respectively (Table 2) [95•]. The use of leucine or its
metabolite beta-hydroxy-beta-methyl-butyrate (HMB) is cur-
rently being evaluated in prospective studies.
Beyond their effects on the muscle, BCAAs may have
other properties including a potential benefit on carcinogene-
sis, possibly through an enhanced immune function and im-
proved hyperinsulinemia (reducing IGF-1- and VEGF-
mediated cell proliferation) [83]. Some studies have suggested
that BCAAs could prevent HCC recurrence after treatment,
although a recent meta-analysis concluded a nonstatistically
significant effect [97].More recently, an RCT in patients treat-
ed with radiofrequency ablation observed that oral supple-
mentation with a BCAA-enriched supplement was associated
with a decrease in HCC recurrence, better event-free survival,
and better quality of life over a median follow-up period of 3.9
years (with similar total calorie and protein intake in both
groups) [92•]. The effects of BCAAs on insulin resistance in
cirrhosis remain unclear. A detailed description of the various
potential targets and mechanisms of action of BCAAs is out-
side the scope of this review and can be found elsewhere [83].
Other Macronutrients Composition and Specific Diets
Although it is recommended inMAFLD, no prospective stud-
ies have looked at the impact of the MD in cirrhosis of any
etiology, and the optimal proportion of fat and CHOs in the
diet is unknown. In patients with ascites, the daily sodium
intake should be moderate (~ 80 mmol, corresponding to 5 g
of added salt) to keep the diet palatable [81••].
Efficacy of Energy/Calorie and Protein
Supplementation
Several studies have shown benefits of calorie and protein
supplementation in patients with cirrhosis on various
nutrition-related outcomes, mostly reflecting muscle mass
(mid-arm muscle circumference, triceps skinfold thickness,
CT-derived skeletal muscle index, DEXA, BIA with phase
angle) and function (handgrip strength, cardiopulmonary en-
durance through 6-min walk test [6MWT], short physical per-
formance battery, and Liver Frailty Index) [80••]. Other stud-
ies have observed benefits on clinical outcomes including in-
fections, ascites, HE, complications after hepatectomy and
liver transplantation, and some even on mortality (Fig. 1b),

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The discrepancy of findings and the inability of meta-analyses
to draw firm conclusions on the prevention of complications
in cirrhosis with DI can be explained by the significant study
heterogeneity in design, included populations, type and dura-
tion of the intervention, presence and characteristics of the
control group (including total daily calorie and protein intake
in comparison to the treatment group, which is inconsistently
reported), and follow-up. Nutritional supplementation may
not be able to reverse some of the pathophysiological mecha-
nisms ofmalnutrition (i.e., malabsorption, anabolic resistance)
and could be futile in some specific situations, but reliable
tools to predict who will or will not respond to nutritional
therapy are not currently available. Therefore, it is reasonable
to attempt DI in all patients with cirrhosis and malnutrition.
Moreover, the intervention should last at least 3–6 months
before concluding to any effect. Importantly, the involvement
of a dietician in the management of cirrhosis was associated
with better survival in a retrospective study [104].
Special Considerations in Cirrhosis
Timing of Supplementation
Since cirrhosis is a state of accelerated starvation (reached in
only 10 h vs. 2–3 days in healthy individuals [105]), the timing
of oral intake is of utmost importance. Fasting periods should
be limited by the use of small and frequent meals of an LES and
a breakfast. An earlier RCT showed that LES over a 12-month
period improved total body protein, while the same supplement
taken during daytime did not and was associated with a trend
towards more complications, death, and transplantation [106].
The optimal caloric content of the LES has not been clearly
defined, although some authors suggest a high caloric content
(200–300 kcal) with a sufficient amount of CHOs (50 g) [107]
and a source of protein, including BCAAs.
Route of Supplementation
The patient’s oral intake must be evaluated regularly to ensure
that the aforementioned targets are reached, otherwise oral nu-
tritional supplementation should be implemented. The latter
may however be difficult to tolerate for some patients, especially
those with more advanced cirrhosis and dysgeusia, anorexia, or
nausea. In this case, enteral nutrition (EN) should be strongly
considered, at least temporarily. As for parenteral nutrition, ex-
perts agree that it should be reserved for patients with moderate
to severe malnutrition who cannot adequately be fed by the oral
and/or enteral route or who have contraindications to EN.
The feasibility of EN in the outpatient setting has recently
been demonstrated in a retrospective case series looking at 14
patients with refractory ascites who failed to improve with oral
nutritional support over a prior mean of 5 months (reasons not
specified but likely due to intolerance) [108]. An outpatient-
based, continuous, and supplementary EN (with a standard,
fiber-enriched polymeric feed) for a median of 7 weeks, in
addition to oral intake, was associated with significant bene-
fits: an improvement in the nutritional status and handgrip
strength, a significant improvement in ascites control with a
decreased need for paracentesis, and a trend towards an im-
provement in the MELD score. Although all patients required
reinsertion of the feeding tube at least once due to dislodge-
ment or blockage, EN was overall well tolerated.
Combining Nutritional Interventions
with Physical Exercise
While in MAFLD, PE mainly exerts its positive effects
through weight loss, in cirrhosis, however, this effect seems
to occur through maintaining/increasing muscle mass. The
beneficial effects of PE on aerobic capacity, sarcopenia, and
quality of life have repeatedly been shown in this population
[109]. However, most of the studies evaluating the effects of
exercise in cirrhosis incorporated a DI, and the observed ef-
fects could be due to diet alone or to a synergistic effect of diet
and PE on muscle mass. Moreover, not all studies systemati-
cally report the patients’ actual mean calorie and protein in-
take [110, 111]. Studies looking at the effect of PE alone in
cirrhosis are rare, and the isolated effect of physical exercise
has not been well defined.
In a recent RCT in 39 patients with Child–Pugh A and B
cirrhosis showing a beneficial effect of a 12-week resistance
training program on muscle strength and size, both arms re-
ceived nutritional counseling by a dietician, regular phone
calls, and oral supplementation when the daily protein intake
was under 1.2 g/kg [112•]. Although the total protein intake
was insufficient at the beginning of the study in both groups, it
reached the target amount at the second dietician visit, show-
ing the efficacy of the intervention. This was also observed in
an earlier Canadian pilot RCT [113]. A study from the UK
showing the feasibility of a hospital-based training program
offered structured nutritional advice in both arms based on the
EASL recommendations [114]. Two studies have also dem-
onstrated a beneficial effect of a combined nutritional and PE
intervention on portal pressure [115•, 116].
Since the benefits of PE depend on adequate substrate re-
serves, some authors have suggested optimizing the nutrition-
al status of patients prior to starting an exercise program [117].
To compensate for the exercise-induced calorie expenditure,
the consumption of an additional 250–300 kcal on exercise
days [113] or a 20% increase in the caloric intake when fol-
lowing an exercise program [116] has been recommended.
Several recent studies have looked at the potential syner-
gistic effect of PE (especially resistance training exercises)
and BCAA supplementation. A pilot RCT showed that
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combining BCAA supplementation with a home-based PE
program improved 6-min walk test (6MWT) distance and
psoas muscle index more than BCAA supplementation alone
(both groups also had a daily protein target intake of 1.2–1.5
g/kg) [118]. An uncontrolled study showed that BCAA sup-
plementation and walking (2000 steps/day) increased muscle
mass and function compared to baseline [119], while another
small uncontrolled trial showed that BCAA supplementation
and a home-based exercise program for 12 months improved
aerobic capacity and glycemic control [120].
Regarding patients with cirrhosis and obesity, we previous-
ly showed that a 16-week intensive lifestyle intervention
consisting of a personalized, hypocaloric, normoproteic diet,
and 60 min/week of supervised PE led to an improvement in
body weight and portal pressure in patients with compensated
cirrhosis [115•]. Although the study used a combined inter-
vention, it is likely that the hypocaloric diet was a major con-
tributor to the observed weight loss. More studies are needed
in this field, given the obesity pandemic and the high preva-
lence of sarcopenia in this population [121].
Conclusions
As highlighted in this review, dietary interventions have been
proven effective in treating MAFLD/MASH in several large
and well-conducted studies. The mainstay in overweight/
obese patients remains a daily (continuous or in an intermittent
fashion) energy deficit of 500–1000 kcal, with a gradual re-
duction of 7–10% of body weight, while lean patients might
benefit from a reduction by 3–5%. Dietary adjustments should
include increased intake of unprocessed foods including fruits
and vegetables, whole grains, fiber, and unsaturated FAs, for
example, through the MD. Refined CHOs, SFAs, and red and
processed meats should be limited.
On the other hand, the amount and quality of data regarding
dietary interventions aimed at treating and reverting malnutri-
tion in cirrhosis are more limited. Meta-analyses could not
prove the efficacy of DI in cirrhosis, probably in part due to
the heterogeneity of studies in this field. DI including BCAAs
supplementation (especially as a late snack) in addition to
calorie and protein supplementation have demonstrated the
potential of improving clinical outcomes in this setting.
There are many challenges to the applicability of these
interventions in both MAFLD and cirrhosis populations.
Adherence from the healthcare providers to nutritional recom-
mendations remains suboptimal, and guidelines need to in-
clude pragmatic and feasible recommendations to improve
adherence. In addition, and maybe most importantly,
healthcare providers and patients need to be educated on mal-
nutrition and its impact on the evolution of chronic liver dis-
eases [122]. As for patients’ awareness and empowerment,
simple educational interventions, such as a simple nutrition
education class followed by reinforcement phone calls, have
been shown to be beneficial [78, 123–125].
The success of DI also strongly depends on proper screen-
ing and identification of patients who might benefit from them
and from the availability of a structured and well-connected
multidisciplinary team. This must include, in addition to the
hepatologist and an exercise specialist, a registered nutrition-
ist, who can properly evaluate the patient’s nutritional status
and provide tailored recommendations (taking also into ac-
count the patient’s preferences and socioeconomic factors),
as well as retroaction and strategy modifications if objectives
are not met. The support of a psychologist might be required
to improve adherence, particularly in patients with obesity and
in patients with anxiety and depression (frequently observed
in obese patients with MAFLD and in patients with cirrhosis).
Barriers to the implementation of nutritional interventions
need to be identified early and optimized, since these are fre-
quent, particularly in patients with cirrhosis [126]. Finally,
further studies should focus on how new technologies can
be applied in this field, for instance, to increase adherence to
DI (e.g., reinforcement strategies via reminders) or to make
expert knowledge more universally available (e.g., web-based
programs). Well-designed randomized controlled studies
adding targeted DI to standard of care vs. standard of care
alone with robust endpoints (e.g., decrease of complications
or mortality) in patients with cirrhosis and in particular de-
compensated cirrhosis are a major unmet need in hepatology.
Acknowledgements EVL is recipient of the Canadian Association for the
Study of the Liver CASL-CLF Clinical Hepatology Fellowship. NL is sup-
ported by the Stiftung für Leberkrankheiten, Bern. CR is recipient of the
Protected Research Time Grant for PhD students of the University of Bern.
Funding Open Access funding provided by Universität Bern.
Declarations
Conflict of Interest The authors have no potential conflicts (financial,
professional, or personal) that are relevant to the manuscript to disclose.
Human and Animal Rights and Informed Consent This article does not
contain any studies with human or animal subjects performed by any of
the authors.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adap-
tation, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source, pro-
vide a link to the Creative Commons licence, and indicate if changes were
made. The images or other third party material in this article are included
in the article's Creative Commons licence, unless indicated otherwise in a
credit line to the material. If material is not included in the article's
Creative Commons licence and your intended use is not permitted by
statutory regulation or exceeds the permitted use, you will need to obtain




Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Di Ciaula A, Baj J, Garruti G, Celano G, De Angelis M, Wang
HH, et al. Liver steatosis, gut-liver axis, microbiome and environ-
mental factors. A never-ending bidirectional cross-talk. J Clin
Med. 2020;9(8).
2.• Geier A, Tiniakos D, Denk H, Trauner M. From the origin of
NASH to the future of metabolic fatty liver disease. Gut. 2021.
Recent review on NASH and MAFLD.
3. Morse CG, McLaughlin M, Matthews L, Proschan M, Thomas F,
Gharib AM, et al. Nonalcoholic steatohepatitis and hepatic fibrosis
in HIV-1-monoinfected adults with elevated aminotransferase
levels on antiretroviral therapy. Clin Infect Dis. 2015;60(10):
1569–78.
4. Pembroke T, Deschenes M, Lebouche B, Benmassaoud A,
Sewitch M, Ghali P, et al. Hepatic steatosis progresses faster in
HIV mono-infected than HIV/HCV co-infected patients and is
associated with liver fibrosis. J Hepatol. 2017;67(4):801–8.
5. Vodkin I, Valasek MA, Bettencourt R, Cachay E, Loomba R.
Clinical, biochemical and histological differences between HIV-
associated NAFLD and primary NAFLD: a case-control study.
Aliment Pharmacol Ther. 2015;41(4):368–78.
6. Nunez M. Clinical syndromes and consequences of antiretroviral-
related hepatotoxicity. Hepatology (Baltimore, Md). 2010;52(3):
1143–55.
7. Guaraldi G, Lonardo A,Maia L, Palella FJ, Jr. Metabolic concerns
in aging HIV-infected persons: from serum lipid phenotype to
fatty liver. AIDS (London, England). 2017;31 Suppl 2:S147-
Ss56.
8. Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser
S, et al. Weight gain following initiation of antiretroviral therapy:
risk factors in randomized comparative clinical trials. Clin Infect
Dis. 2020;71(6):1379–89.
9. Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N,
Masenya M, et al. Dolutegravir plus two different prodrugs of
tenofovir to treat HIV. N Engl J Med. 2019;381(9):803–15.
10. Bourgi K, Jenkins CA, Rebeiro PF, Palella F, Moore RD, Altoff
KN, et al. Weight gain among treatment-naive persons with HIV
starting integrase inhibitors compared to non-nucleoside reverse
transcriptase inhibitors or protease inhibitors in a large observa-
tional cohort in the United States and Canada. J Int AIDS Soc.
2020;23(4):e25484.
11. Bakal DR, Coelho LE, Luz PM, Clark JL, De Boni RB, Cardoso
SW, et al. Obesity following ART initiation is common and influ-
enced by both traditional and HIV-/ART-specific risk factors. J
Antimicrob Chemother. 2018;73(8):2177–85.
12. Hsu R, Brunet L, Fusco JS, Mounzer K, Vannappagari V,
Henegar C, et al. 341. Risk of type 2 diabetes mellitus after anti-
retroviral therapy initiation in individuals living with HIV in the
United States: open forum infect dis. 2019;6(Suppl 2):S181-2.
https://doi.org/10.1093/ofid/ofz360.414. eCollection 2019 Oct.
13. Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current
guidelines for the management of non-alcoholic fatty liver disease:
a systematic review with comparative analysis. World J
Gastroenterol. 2018;24(30):3361–73.
14. EACS. European AIDS Clinical Society Guidelines 2020.
15. WHO. Diet, nutrition and the prevention of chronic diseases. 2003
16. Haidari F, Hojhabrimanesh A, Helli B, Seyedian S-S, Ahmadi-
Angali K, Abiri B. A hypocaloric high-protein diet supplemented
withβ-cryptoxanthin improves non-alcoholic fatty liver disease: a
randomized controlled trial. BMC Gastroenterol. 2020;20(1):349.
17. Nourian M, Askari G, Golshiri P, Miraghajani M, Shokri S, Arab
A. Effect of lifestyle modification education based on health belief
model in overweight/obese patients with non-alcoholic fatty liver
disease: a parallel randomized controlled clinical trial. Clin Nutr
ESPEN. 2020;38:236–41.
18. Campanella A, Iacovazzi PA, Misciagna G, Bonfiglio C, Mirizzi
A, Franco I, et al. The effect of three Mediterranean diets on
remnant cholesterol and non-alcoholic fatty liver disease: a sec-
ondary analysis. Nutrients. 2020;12(6).
19. Della Pepa G, Vetrani C, Brancato V, Vitale M, Monti S, Annuzzi
G, et al. Effects of a multifactorial ecosustainable isocaloric diet on
liver fat in patients with type 2 diabetes: randomized clinical trial.
BMJ Open Diabetes Res Care. 2020;8(1).
20. Cai H, Qin Y-L, Shi Z-Y, Chen J-H, Zeng M-J, Zhou W, et al.
Effects of alternate-day fasting on body weight and dyslipidaemia
in patients with non-alcoholic fatty liver disease: a randomised
controlled trial. BMC Gastroenterol. 2019;19(1):219.
21. Marin-Alejandre BA, Abete I, Cantero I, Monreal JI, Elorz M,
Herrero JI, et al. The metabolic and hepatic impact of two person-
alized dietary strategies in subjects with obesity and nonalcoholic
fatty liver disease: the fatty liver in obesity (FLiO) randomized
controlled trial. Nutrients. 2019;11(10).
22. Rosqvist F, Kullberg J, Ståhlman M, Cedernaes J, Heurling K,
Johansson H-E, et al. Overeating saturated fat promotes fatty liver
and ceramides compared with polyunsaturated fat: a randomized
trial. J Clin Endocrinol Metab. 2019;104(12):6207–19.
23. Arab A, Hadi A, Moosavian SP, Rafie N, Hajianfar H. The effect
of nutrition education program on overweight/obese patients with
non-alcoholic fatty liver disease: a single-blind parallel random-
ized controlled trial. Clin Nutr Res. 2019;8(3):238–46.
24. Gepner Y, Shelef I, Komy O, Cohen N, Schwarzfuchs D, Bril N,
et al. The beneficial effects of Mediterranean diet over low-fat diet
may be mediated by decreasing hepatic fat content. J Hepatol.
2019;71(2):379–88.
25. Gepner Y, Shelef I, Schwarzfuchs D, Zelicha H, Tene L, Yaskolka
Meir A, et al. Effect of distinct lifestyle interventions on mobilization
of fat storage pools: CENTRAL magnetic resonance imaging ran-
domized controlled trial. Circulation. 2018;137(11):1143–57.
26. Shojasaadat F, Ayremlou P, Hashemi A, Mehdizadeh A, Zarrin R. A
randomized controlled trial comparing effects of a low-energy diet
with n-3 polyunsaturated fatty acid supplementation in patients with
non-alcoholic fatty liver disease. J Res Med Sci. 2019;24.
27. Willmann C, Heni M, Linder K, Wagner R, Stefan N, Machann J,
et al. Potential effects of reduced red meat compared with in-
creased fiber intake on glucose metabolism and liver fat content:
a randomized and controlled dietary intervention study. Am J Clin
Nutr. 2019;109(2):288–96.
28. Jang EC, Jun DW, Lee SM, Cho YK, Ahn SB. Comparison of
efficacy of low-carbohydrate and low-fat diet education programs
in non-alcoholic fatty liver disease: a randomized controlled study.
Hepatol Res. 2018;48(3):E22–E9.
29.• Wong VW-S, Wong GL-H, Chan RS-M, Shu SS-T, Cheung BH-
K, Li LS, et al. Beneficial effects of lifestyle intervention in non-
obese patients with non-alcoholic fatty liver disease. J Hepatol.
2018;69(6):1349–56 RCT demonstrating beneficial effects of
modest weight loss also for lean individuals with MAFLD.
30. Properzi C, O'Sullivan TA, Sherriff JL, Ching HL, Jeffrey GP,
Buckley RF, et al. Ad libitum Mediterranean and low-fat diets
both significantly reduce hepatic steatosis: a randomized con-
trolled trial. Hepatology. 2018;68(5):1741–54.
31. Chan DFY, So HK, Hui SCN, Chan RSM, Li AM, Sea MM, et al.
Dietitian-led lifestyle modification programme for obese Chinese
adolescents with non-alcoholic fatty liver disease: a randomized
controlled study. Int J Obes. 2018;42(9):1680–90.
Curr Hepatology Rep
32. Katsagoni CN, Papatheodoridis GV, Ioannidou P, Deutsch M,
Alexopoulou A, Papadopoulos N, et al. Improvements in clinical
characteristics of patients with non-alcoholic fatty liver disease, after
an intervention based on the Mediterranean lifestyle: a randomised
controlled clinical trial. Br J Nutr. 2018;120(2):164–75.
33. Holmer ML, C.; Petersson, S.; Moshtaghi-Svensson, J.; Tillander,
V.; Brismar, TB.; Hagström, H.; Stål, P. Treatment of NAFLD
with intermittent calorie restriction or lowcarb high-fat diet — a
randomized controlled trial. JHEP reports: innovation in
hepatology. 2021:100256.
34. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic
fatty liver disease: improvement in liver histological analysis with
weight loss. Hepatology. 2004;39(6):1647–54.
35.• Koutoukidis DA, Astbury NM, Tudor KE, Morris E, Henry JA,
Noreik M, et al. Association of weight loss interventions with
changes in biomarkers of nonalcoholic fatty liver disease: a sys-
tematic review and meta-analysis. JAMA Intern Med.
2019;179(9):1262–71 Meta-analysis showing association be-
tween weight loss interventions and improved liver bio-
markers in MAFLD.
36. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S,
et al. Therapeutic effects of restricted diet and exercise in obese
patients with fatty liver. J Hepatol. 1997;27(1):103–7.
37. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA.
Orlistat for overweight subjects with nonalcoholic steatohepatitis:
a randomized, prospective trial. Hepatology. 2009;49(1):80–6.
38. Malespin MH, Barritt AS, Watkins SE, Schoen C, Tincopa MA,
Corbin KD, et al. Weight loss and weight regain in usual clinical
practice: results from the TARGET-NASH observational cohort.
Clin Gastroenterol Hepatol. 2021.
39. Hernandez Roman J, Patel S. Why do lifestyle recommendations
fail in most patients with nonalcoholic fatty liver disease?
Gastroenterol Clin N Am. 2020;49(1):95–104.
40. Lazo M, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati
FL, et al. Effect of a 12-month intensive lifestyle intervention on
hepatic steatosis in adults with type 2 diabetes. Diabetes Care.
2010;33(10):2156–63.
41. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M,
Wands JR, et al. Randomized controlled trial testing the effects of
weight loss on nonalcoholic steatohepatitis (NASH). Hepatology.
2010;51(1):121–9.
42. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-
Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss
through lifestyle modification significantly reduces features of nonal-
coholic steatohepatitis. Gastroenterology. 2015;149(2):367–78.e5.
43. Hamurcu Varol P, Kaya E, Alphan E, Yilmaz Y. Role of intensive
dietary and lifestyle interventions in the treatment of lean nonal-
coholic fatty liver disease patients. Eur J Gastroenterol Hepatol.
2020;32(10):1352–7.
44. Koopman KE, Caan MWA, Nederveen AJ, Pels A, Ackermans
MT, Fliers E, et al. Hypercaloric diets with increased meal fre-
quency, but not meal size, increase intrahepatic triglycerides: a
randomized controlled trial. Hepatology. 2014;60(2):545–53.
45. Rynders CA, Thomas EA, Zaman A, Pan Z, Catenacci VA,
Melanson EL. Effectiveness of intermittent fasting and time-
restricted feeding compared to continuous energy restriction for
weight loss. Nutrients. 2019;11(10).
46. Johari MI, Yusoff K, Haron J, Nadarajan C, Ibrahim KN, Wong
MS, et al. A randomised controlled trial on the effectiveness and
adherence of modified alternate-day calorie restriction in improv-
ing activity of non-alcoholic fatty liver disease. Sci Rep.
2019;9(1):11232.
47. Toshimitsu K,Matsuura B, Ohkubo I, Niiya T, Furukawa S, Hiasa
Y, et al. Dietary habits and nutrient intake in non-alcoholic
steatohepatitis. Nutrition. 2007;23(1):46–52.
48. Luukkonen PK, Sädevirta S, Zhou Y, Kayser B, Ali A, Ahonen L,
et al. Saturated fat is more metabolically harmful for the human
liver than unsaturated fat or simple sugars. Diabetes Care.
2018;41(8):1732–9.
49. Rosqvist F, Iggman D, Kullberg J, Cedernaes J, Johansson H-E,
Larsson A, et al. Overfeeding polyunsaturated and saturated fat
causes distinct effects on liver and visceral fat accumulation in
humans. Diabetes. 2014;63(7):2356–68.
50. Errazuriz I, Dube S, Slama M, Visentin R, Nayar S, O’Connor H,
et al. Randomized controlled trial of a MUFA or fiber-rich diet on
hepatic fat in prediabetes. J Clin Endocrinol Metab. 2017;102(5):
1765–74.
51. Lu W, Li S, Li J, Wang J, Zhang R, Zhou Y, et al. Effects of
omega-3 fatty acid in nonalcoholic fatty liver disease: a meta-
analysis. Gastroenterol Res Pract. 2016;2016:1459790.
52. Musa-Veloso K, Venditti C, Lee HY, Darch M, Floyd S, West S,
et al. Systematic review and meta-analysis of controlled interven-
tion studies on the effectiveness of long-chain omega-3 fatty acids
in patients with nonalcoholic fatty liver disease. Nutr Rev.
2018;76(8):581–602.
53. Parker HM, Cohn JS, O'Connor HT, Garg ML, Caterson ID,
George J, et al. Effect of fish oil supplementation on hepatic and
visceral fat in overweight men: a randomized controlled trial.
Nutrients. 2019;11(2).
54. Green CJ, Pramfalk C, Charlton CA, Gunn PJ, Cornfield T,
Pavlides M, et al. Hepatic de novo lipogenesis is suppressed and
fat oxidation is increased by omega-3 fatty acids at the expense of
glucose metabolism. BMJ Open Diabetes Res Care. 2020;8(1).
55. Argo CK, Patrie JT, Lackner C, Henry TD, de Lange EE,
Weltman AL, et al. Effects of n-3 fish oil on metabolic and histo-
logical parameters in NASH: a double-blind, randomized,
placebo-controlled trial. J Hepatol. 2015;62(1):190–7.
56. Haghighatdoost F, Salehi-Abargouei A, Surkan PJ, Azadbakht L.
The effects of low carbohydrate diets on liver function tests in
nonalcoholic fatty liver disease: a systematic review and meta-
analysis of clinical trials. J Res Med Sci. 2016;21:53.
57. Skytte MJ, Samkani A, Petersen AD, Thomsen MN, Astrup A,
Chabanova E, et al. A carbohydrate-reduced high-protein diet im-
proves HbA1c and liver fat content in weight stable participants
with type 2 diabetes: a randomised controlled trial. Diabetologia.
2019;62(11):2066–78.
58. Mardinoglu A, Wu H, Bjornson E, Zhang C, Hakkarainen A,
Räsänen SM, et al. An integrated understanding of the rapid met-
abolic benefits of a carbohydrate-restricted diet on hepatic
steatosis in humans. Cell Metab. 2018;27(3):559-71.e5.
59. Luukkonen PK, Dufour S, Lyu K, Zhang X-M, Hakkarainen A,
Lehtimäki TE, et al. Effect of a ketogenic diet on hepatic steatosis
and hepatic mitochondrial metabolism in nonalcoholic fatty liver
disease. Proc Natl Acad Sci U S A. 2020;117(13):7347–54.
60. Vilar-Gomez E, Athinarayanan SJ, Adams RN, Hallberg SJ,
Bhanpuri NH, McKenzie AL, et al. Post hoc analyses of surrogate
markers of non-alcoholic fatty liver disease (NAFLD) and liver
fibrosis in patients with type 2 diabetes in a digitally supported
continuous care intervention: an open-label, non-randomised con-
trolled study. BMJ Open. 2019;9(2):e023597.
61. Chiu S, Sievenpiper JL, de Souza RJ, Cozma AI, Mirrahimi A,
Carleton AJ, et al. Effect of fructose on markers of non-alcoholic
fatty liver disease (NAFLD): a systematic review and meta-
analysis of controlled feeding trials. Eur J Clin Nutr. 2014;68(4):
416–23.
62.•• Schwimmer JB, Ugalde-Nicalo P,Welsh JA, Angeles JE, Cordero
M,HarlowKE, et al. Effect of a low free sugar diet vs usual diet on
nonalcoholic fatty liver disease in adolescent boys: a randomized
clinical trial. JAMA. 2019;321(3):256–65Controlled trial show-
ing the benefit of a relatively simple intervention targeting
intake of free sugar on steatosis among adolescent boys.
Curr Hepatology Rep
63. Reynolds A, Mann J, Cummings J, Winter N, Mete E, Morenga
LT. Carbohydrate quality and human health: a series of systematic
reviews and meta-analyses. Lancet. 2019;393(10170):434–45.
64. Wehmeyer MH, Zyriax B-C, Jagemann B, Roth E, Windler E,
Schulze Zur Wiesch J, et al. Nonalcoholic fatty liver disease is
associated with excessive calorie intake rather than a distinctive
dietary pattern. Medicine (Baltimore). 2016;95(23):e3887.
65. Zolfaghari H, Askari G, Siassi F, Feizi A, Sotoudeh G. Intake of
nutrients, fiber, and sugar in patients with nonalcoholic fatty liver
disease in comparison to healthy individuals. Int J Prev Med.
2016;7:98.
66. Cantero I, Abete I, Monreal JI, Martinez JA, Zulet MA. Fruit fiber
consumption specifically improves liver health status in obese
subjects under energy restriction. Nutrients. 2017;9(7):667.
67. Xu C, Markova M, Seebeck N, Loft A, Hornemann S, Gantert T,
et al. High-protein diet more effectively reduces hepatic fat than
low-protein diet despite lower autophagy and FGF21 levels. Liver
Int. 2020.
68. Wolk A. Potential health hazards of eating red meat. J Intern Med.
2017;281(2):106–22.
69. Alferink LJ, Kiefte-de Jong JC, Erler NS, Veldt BJ, Schoufour JD,
de Knegt RJ, et al. Association of dietary macronutrient composi-
tion and non-alcoholic fatty liver disease in an ageing population:
the Rotterdam study. Gut. 2019;68(6):1088–98.
70. McCarty MF. GCN2 and FGF21 are likely mediators of the pro-
tection from cancer, autoimmunity, obesity, and diabetes afforded
by vegan diets. Med Hypotheses. 2014;83(3):365–71.
71. Markova M, Pivovarova O, Hornemann S, Sucher S, Frahnow T,
Wegner K, et al. Isocaloric diets high in animal or plant protein
reduce liver fat and inflammation in individuals with type 2 dia-
betes. Gastroenterology. 2017;152(3):571–85.e8.
72. Keys A, Menotti A, Karvonen MJ, Aravanis C, Blackburn H,
Buzina R, et al. The diet and 15-year death rate in the Seven
Countries Study. Am J Epidemiol. 1986;124(6):903–15.
73. Fidanza F, Alberti A, Lanti M, Menotti A. Mediterranean
Adequacy Index: correlation with 25-year mortality from coro-
nary heart disease in the Seven Countries Study. Nutr Metab
Cardiovasc Dis. 2004;14(5):254–8.
74. Davis C, Bryan J, Hodgson J, Murphy K. Definition of the
Mediterranean diet; a literature review. Nutrients. 2015;7(11):
9139–53.
75. RyanMC, Itsiopoulos C, Thodis T, Ward G, Trost N, Hofferberth
S, et al. The Mediterranean diet improves hepatic steatosis and
insulin sensitivity in individuals with non-alcoholic fatty liver dis-
ease. J Hepatol. 2013;59(1):138–43.
76. Easl–Easd–Easo. EASL–EASD–EASO Clinical practice guide-
lines for the management of non-alcoholic fatty liver disease. J
Hepatol. 2016;64(6):1388–402.
77. Silva Figueiredo P, Inada AC, Ribeiro Fernandes M, Granja
Arakaki D, Freitas KdC, Avellaneda Guimarães RdC, et al. An
overview of novel dietary supplements and food ingredients in
patients with metabolic syndrome and non-alcoholic fatty liver
disease. Molecules (Basel, Switzerland). 2018;23(4).
78. Liu L, Li P, Liu Y, Zhang Y. Efficacy of probiotics and synbiotics
in patients with nonalcoholic fatty liver disease: a meta-analysis.
Dig Dis Sci. 2019;64(12):3402–12.
79. Hayat U, Siddiqui AA, Okut H, Afroz S, Tasleem S, Haris A. The
effect of coffee consumption on the non-alcoholic fatty liver dis-
ease and liver fibrosis: a meta-analysis of 11 epidemiological stud-
ies. Ann Hepatol. 2020.
80.•• Plauth M, Bernal W, Dasarathy S, Merli M, Plank LD, Schutz T,
et al. ESPEN guideline on clinical nutrition in liver disease. Clin
Nutr. 2019;38(2):485–521 ESPEN recommendations on nutri-
tion in liver disease.
81.•• European Association for the Study of the Liver. Electronic ad-
dress EEE, European Association for the Study of the L. EASL
Clinical practice guidelines on nutrition in chronic liver disease. J
Hepatol. 2019;70(1):172–93 EASL recommendations on nutri-
tion in liver disease.
82. Bajaj JS, Idilman R, Mabudian L, Hood M, Fagan A, Turan D,
et al. Diet affects gut microbiota and modulates hospitalization
risk differentially in an international cirrhosis cohort.
Hepatology. 2018;68(1):234–47.
83. Tajiri K, ShimizuY. Branched-chain amino acids in liver diseases.
Transl Gastroenterol Hepatol. 2018;3:47.
84. Marchesini G, Bianchi G, Merli M, Amodio P, Panella C,
Loguercio C, et al. Nutritional supplementation with branched-
chain amino acids in advanced cirrhosis: a double-blind, random-
ized trial. Gastroenterology. 2003;124(7):1792–801.
85. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A,
et al. Effects of oral branched-chain amino acid granules on event-
free survival in patients with liver cirrhosis. Clin Gastroenterol
Hepatol. 2005;3(7):705–13.
86. Hernández Conde M, Llop E, Tormo B, Perelló C, López-Gómez
M, Abad Guerra J, et al. Supplementation with branched-chain
amino acids improves muscle mass of cirrhotic patients with
sarcopenia. J Hepatol. 2020;73:S37–S8.
87. Park JG, Tak WY, Park SY, Kweon YO, Chung WJ, Jang BK,
et al. Effects of branched-chain amino acid (BCAA) supplemen-
tation on the progression of advanced liver disease: a Korean
nationwide, multicenter, prospective, observational, cohort study.
Nutrients. 2020;12(5).
88. Vidot H, Cvejic E, Finegan LJ, Shores EA, Bowen DG, Strasser
SI, et al. Supplementation with synbiotics and/or branched chain
amino acids in hepatic encephalopathy: a pilot randomised
placebo-controlled clinical study. Nutrients. 2019;11(8).
89. Kitajima Y, Takahashi H, Akiyama T, Murayama K, Iwane S,
Kuwashiro T, et al. Supplementation with branched-chain amino
acids ameliorates hypoalbuminemia, prevents sarcopenia, and re-
duces fat accumulation in the skeletal muscles of patients with
liver cirrhosis. J Gastroenterol. 2018;53(3):427–37.
90. Ruiz-Margain A, Mendez-Guerrero O, Roman-Calleja BM,
Gonzalez-Rodriguez S, Fernandez-Del-Rivero G, Rodriguez-
Cordova PA, et al. Dietary management and supplementation
with branched-chain amino acids in cirrhosis of the liver. Rev
Gastroenterol Mex. 2018;83(4):424–33.
91. Uojima H, Sakurai S, Hidaka H, Kinbara T, Sung JH, Ichita C,
et al. Effect of branched-chain amino acid supplements on muscle
strength and muscle mass in patients with liver cirrhosis. Eur J
Gastroenterol Hepatol. 2017;29(12):1402–7.
92.• Nojiri S, Fujiwara K, Shinkai N, Iio E, Joh T. Effects of branched-
chain amino acid supplementation after radiofrequency ablation
for hepatocellular carcinoma: a randomized trial. Nutrition.
2017;33:20–7 RCT with a long follow-up period showing an
improved event-free survival with BCAA supplementation af-
ter RFA for HCC.
93. Kikuchi Y, Hiroshima Y, Matsuo K, Kawaguchi D, Murakami T,
Yabushita Y, et al. A randomized clinical trial of preoperative
administration of branched-chain amino acids to prevent postop-
erative ascites in patients with liver resection for hepatocellular
carcinoma. Ann Surg Oncol. 2016;23(11):3727–35.
94. Furuichi Y, Imai Y, Miyata Y, Sugimoto K, Sano T, Taira J, et al.
Branched-chain amino acid-enriched nutrient increases blood
platelet count in patients after endoscopic injection sclerotherapy.
Hepatol Res. 2016;46(11):1129–36.
95.• Ooi PH, Gilmour SM, Yap J, Mager DR. Effects of branched
chain amino acid supplementation on patient care outcomes in
adults and children with liver cirrhosis: a systematic review. Clin
Nutr ESPEN. 2018;28:41–51 Important systematic review
summarizing the effects of BCAA supplementation in
cirrhosis.
Curr Hepatology Rep
96. Gluud LL, Dam G, Les I, Marchesini G, Borre M, Aagaard NK,
et al. Branched-chain amino acids for people with hepatic enceph-
alopathy. Cochrane Database Syst Rev. 2017;5:CD001939.
97. Chen L, Chen Y, Wang X, Li H, Zhang H, Gong J, et al. Efficacy
and safety of oral branched-chain amino acid supplementation in
patients undergoing interventions for hepatocellular carcinoma: a
meta-analysis. Nutr J. 2015;14:67.
98. Chen CJ, Wang LC, Kuo HT, Fang YC, Lee HF. Significant
effects of late evening snack on liver functions in patients with
liver cirrhosis: a meta-analysis of randomized controlled trials. J
Gastroenterol Hepatol. 2019;34(7):1143–52.
99. Hanai T, Shiraki M, Imai K, Suetsugu A, Takai K, Shimizu M.
Late evening snack with branched-chain amino acids supplemen-
tation improves survival in patients with cirrhosis. J Clin Med.
2020;9(4).
100. Park JG, Tak WY, Park SY, Kweon YO, Jang SY, Lee YR, et al.
Effects of branched-chain amino acids (BCAAs) on the progres-
sion of advanced liver disease: a Korean nationwide, multicenter,
retrospective, observational, cohort study. Medicine. 2017;96(24):
e6580.
101. Koretz RL, Avenell A, Lipman TO. Nutritional support for liver
disease. Cochrane Database Syst Rev. 2012;5:CD008344.
102. Ney M, Vandermeer B, van Zanten SJ, Ma MM, Gramlich L,
Tandon P. Meta-analysis: oral or enteral nutritional supplementa-
tion in cirrhosis. Aliment Pharmacol Ther. 2013;37(7):672–9.
103. Fialla AD, Israelsen M, Hamberg O, Krag A, Gluud LL.
Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic
review and meta-analysis. Liver Int. 2015;35(9):2072–8.
104. Iwasa M, Iwata K, Hara N, Hattori A, Ishidome M, Sekoguchi-
Fujikawa N, et al. Nutrition therapy using a multidisciplinary team
improves survival rates in patients with liver cirrhosis. Nutrition.
2013;29(11-12):1418–21.
105. Owen OE, Trapp VE, Reichard GA Jr, Mozzoli MA, Moctezuma
J, Paul P, et al. Nature and quantity of fuels consumed in patients
with alcoholic cirrhosis. J Clin Invest. 1983;72(5):1821–32.
106. Plank LD, Gane EJ, Peng S, Muthu C, Mathur S, Gillanders L,
et al. Nocturnal nutritional supplementation improves total body
protein status of patients with liver cirrhosis: a randomized 12-
month trial. Hepatology. 2008;48(2):557–66.
107. Tsien CD, McCullough AJ, Dasarathy S. Late evening snack:
exploiting a period of anabolic opportunity in cirrhosis. J
Gastroenterol Hepatol. 2012;27(3):430–41.
108. Vidot H, Bowen DG, Carey S,McCaughan GW, Allman-Farinelli
M, Shackel NA. Aggressive nutrition intervention reduces ascites
and frequency of paracentesis in malnourished patients with cir-
rhosis and ascites. JGH Open. 2017;1(3):92–7.
109. Williams FR, Berzigotti A, Lord JM, Lai JC, Armstrong MJ.
Review article: impact of exercise on physical frailty in patients
with chronic liver disease. Aliment Pharmacol Ther. 2019;50(9):
988–1000.
110. Kruger C, McNeely ML, Bailey RJ, Yavari M, Abraldes JG,
Carbonneau M, et al. Home exercise training improves exercise
capacity in cirrhosis patients: role of exercise adherence. Sci Rep.
2018;8(1):99.
111. Wallen MP, Keating SE, Hall A, Hickman IJ, Pavey TG,
Woodward AJ, et al. Exercise training is safe and feasible in
patients awaiting liver transplantation: a pilot randomized con-
trolled trial. Liver Transpl. 2019;25(10):1576–80.
112.• Aamann L, Dam G, Borre M, Drljevic-Nielsen A, Overgaard K,
Andersen H, et al. Resistance training increases muscle strength
and muscle size in patients with liver cirrhosis. Clin Gastroenterol
Hepatol. 2020;18(5):1179–87 e6 RCT focusing on the effects of
an exercise program but confirming the efficacy of regular
nutritional advice to help reaching recommended protein in-
take targets.
113. Zenith L, Meena N, Ramadi A, Yavari M, Harvey A, Carbonneau
M, et al. Eight weeks of exercise training increases aerobic capac-
ity and muscle mass and reduces fatigue in patients with cirrhosis.
Clin Gastroenterol Hepatol. 2014;12(11):1920–6 e2.
114. Morkane CM, Kearney O, Bruce DA, Melikian CN, Martin DS.
An outpatient hospital-based exercise training program for pa-
tients with cirrhotic liver disease awaiting transplantation: a feasi-
bility trial. Transplantation. 2020;104(1):97–103.
115.• Berzigotti A, Albillos A, Villanueva C, Genesca J, Ardevol A,
Augustin S, et al. Effects of an intensive lifestyle intervention
program on portal hypertension in patients with cirrhosis and obe-
sity: the SportDiet study. Hepatology. 2017;65(4):1293–305Only
trial looking at a combined lifestyle intervention in obese pa-
tients with cirrhosis, and showing its feasibility and beneficial
effect on portal pressure.
116. Macias-Rodriguez RU, Ilarraza-Lomeli H, Ruiz-Margain A,
Ponce-de-Leon-Rosales S, Vargas-Vorackova F, Garcia-Flores
O, et al. Changes in hepatic venous pressure gradient induced by
physical exercise in cirrhosis: results of a pilot randomized open
clinical trial. Clin Transl Gastroenterol. 2016;7(7):e180.
117. Williams FR, Vallance A, Faulkner T, Towey J, Durman S, Kyte
D, et al. Home-based exercise in patients awaiting liver transplan-
tation: a feasibility study. Liver Transpl. 2019;25(7):995–1006.
118. Chen HW, Ferrando A, White MG, Dennis RA, Xie J, Pauly M,
et al. Home-based physical activity and diet intervention to im-
prove physical function in advanced liver disease: a randomized
pilot trial. Dig Dis Sci. 2020;65:3350–9.
119. Hiraoka A, Michitaka K, Kiguchi D, Izumoto H, Ueki H, Kaneto
M, et al. Efficacy of branched-chain amino acid supplementation
and walking exercise for preventing sarcopenia in patients with
liver cirrhosis. Eur J Gastroenterol Hepatol. 2017;29(12):1416–
23.
120. Nishida Y, Ide Y, Okada M, Otsuka T, Eguchi Y, Ozaki I, et al.
Effects of home-based exercise and branched-chain amino acid
supplementation on aerobic capacity and glycemic control in pa-
tients with cirrhosis. Hepatol Res. 2017;47(3):E193–200.
121. El Sherif O, Dhaliwal A, Newsome PN, Armstrong MJ.
Sarcopenia in nonalcoholic fatty liver disease: new challenges
for clinical practice. Expert Rev Gastroenterol Hepatol.
2020;14(3):197–205.
122. Theodoridis X, Grammatikopoulou MG, Petalidou A, Kontonika
SM, Potamianos SP, Bogdanos DP. A systematic review of med-
ical nutrition therapy guidelines for liver cirrhosis: do we agree?
Nutr Clin Pract. 2020;35(1):98–107.
123. Alavinejad P, Hajiani E, Danyaee B, Morvaridi M. The effect of
nutritional education and continuous monitoring on clinical symp-
toms, knowledge, and quality of life in patients with cirrhosis.
Gastroenterol Hepatol Bed Bench. 2019;12(1):17–24.
124. Hayward KL, Martin JH, Cottrell WN, Karmakar A, Horsfall LU,
Patel PJ, et al. Patient-oriented education and medication manage-
ment intervention for people with decompensated cirrhosis: study
protocol for a randomized controlled trial. Trials. 2017;18(1):339.
125. Chaney AJ, Heckman MG. The benefit of supplemental nutrition
education for severely malnourished patients awaiting liver trans-
plant. Prog Transplant. 2018;28(4):390–3.
126. Ney M, Gramlich L, Mathiesen V, Bailey RJ, Haykowsky M, Ma
M, et al. Patient-perceived barriers to lifestyle interventions in
cirrhosis. Saudi J Gastroenterol. 2017;23(2):97–104.
Publisher’s Note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Curr Hepatology Rep
